Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ipilimumab N01”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Looking for participantsNCT07560488
What this trial is testing

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

Who this might be right for
HCC - Hepatocellular CarcinomaConversion Therapy
Tianjin Medical University Cancer Institute and Hospital 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT07654530
What this trial is testing

Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.

Who this might be right for
Biliary Tract Cancers (BTC)
Tianjin Medical University Cancer Institute and Hospital 107
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07683221
What this trial is testing

SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Shandong Cancer Hospital and Institute 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07487662
What this trial is testing

TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

Who this might be right for
Hepato Cellular Carcinoma (HCC)
Sun Yat-sen University 105
Testing effectiveness (Phase 2)Looking for participantsNCT07422753
What this trial is testing

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

Who this might be right for
Hepatocellular Carcinoma (HCC)
Second Affiliated Hospital, Zhejiang University, School of Medicine 36
Testing effectiveness (Phase 2)Looking for participantsNCT07506109
What this trial is testing

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Who this might be right for
BRAF V600EColorectal CancerSintilimab+4 more
Tianjin Medical University Cancer Institute and Hospital 49
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07715565
What this trial is testing

Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

Who this might be right for
Renal Cell Carcinoma (Kidney Cancer)ImmunotherapyMolecular Targeted Therapy
West China Hospital 66
Large-scale testing (Phase 3)Looking for participantsNCT07643623
What this trial is testing

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 720
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07638631
What this trial is testing

Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer

Who this might be right for
Locally Advanced Gastric Cancer
Chen Lizhu 30